Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 2607  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 »   Next article
 »   Previous article
 »   Table of Contents

 Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded99    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


Year : 2021  |  Volume : 69  |  Issue : 7  |  Page : 17--24

Biomarkers in Migraine

1 Sidney Kimmel Medical College, Thomas Jefferson University, USA
2 Department of Neurology, Thomas Jefferson University, USA

Correspondence Address:
Dr. Stephanie J Nahas
Jefferson Headache Center, 90 0 Walnut Street, Suite 200, Philadelphia, PA 19107
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0028-3886.315988

Rights and Permissions

Background: Disability from migraine has a profound impact on the world's economy. Research has been ongoing to identify biomarkers to aid in diagnosis and treatment. Objective: The aim of this study was to highlight the purported diagnostic and therapeutic migraine biomarkers and their role in precision medicine. Methods: A comprehensive literature search was conducted using PubMed, Google Scholar, and clinicaltrials.gov using keywords: “migraine” OR “headache” combined with “biomarkers” OR “marker.” Other keywords included “serum,” “cerebral spinal fluid,” “inflammatory,” and “neuroimaging.” Results: After a review of 88 papers, we find the literature supports numerous biomarkers in the diagnosis of migraine. Therapeutic biomarkers, while not as extensively published, highlight calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating peptide-38 (PACAP-38) as biomarkers with the most substantiated clinical relevance. Genetic markers mainly focusing on gene mutations with resultant biochemical alterations continue to be studied and show promise. Conclusion: Although there are several proposed biomarkers for migraine, continued research is needed to substantiate their role in clinical practice.


Print this article     Email this article

Online since 20th March '04
Published by Wolters Kluwer - Medknow